Patent · US Active

Anti-CD39 antibodies

US12312410B2 · kind B2 · utility

0Cited by

2References

24Claims

0Family size

Assignee

ELPISCIENCE (SUZHOU) BIOPHARMA, LTD · CN

Inventors

Yangsheng QIU · Shanghai, CN
Meiling SUN · Shanghai, CN
Roumei XING · Shanghai, CN
Dan Xu · Nanjing, CN
Yufei Shi · Shanghai, CN
Jinfeng Zhao · Beijing, CN
Qinglin DU · Shanghai, CN
Zhihao Wu · Shanghai, CN
Rui GAO · Jinan, CN
Robert Arch · Saint Louis, US
Hongtao Lu · Shanghai, CN

Key dates

Filing date	Aug 26, 2020
Grant date	May 27, 2025
Priority date	—
Expiry date	Jun 12, 2043

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided are anti-CD39 antibodies or antigen-binding fragments thereof, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.